These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 8546166)

  • 1. Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis.
    Niwa T; Asada H; Tsutsui S; Miyazaki T
    Am J Nephrol; 1995; 15(6):463-7. PubMed ID: 8546166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding.
    Niwa T; Takeda N; Maeda K; Shibata M; Tatematsu A
    Clin Chim Acta; 1988 Apr; 173(2):127-38. PubMed ID: 3378354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form.
    Niwa T; Aiuchi T; Nakaya K; Emoto Y; Miyazaki T; Maeda K
    Clin Nephrol; 1993 Feb; 39(2):92-6. PubMed ID: 8448924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis.
    Niwa T; Yazawa T; Kodama T; Uehara Y; Maeda K; Yamada K
    Nephron; 1990; 56(3):241-5. PubMed ID: 2077405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced renal clearance of furancarboxylic acid, a major albumin-bound organic acid, in undialyzed uremic patients.
    Sato M; Koyama M; Miyazaki T; Niwa T
    Nephron; 1996; 74(2):419-21. PubMed ID: 8893167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal of protein-bound uraemic toxins by haemodialysis.
    Niwa T
    Blood Purif; 2013; 35 Suppl 2():20-5. PubMed ID: 23676831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane.
    Lesaffer G; De Smet R; Lameire N; Dhondt A; Duym P; Vanholder R
    Nephrol Dial Transplant; 2000 Jan; 15(1):50-7. PubMed ID: 10607767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and quantification of a protein-bound ligand in uremic serum.
    Takeda N; Niwa T; Tatematsu A; Suzuki M
    Clin Chem; 1987 May; 33(5):682-5. PubMed ID: 3568353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Plasma concentrations of anionic uremic toxins in hemodialysis patients and their effects on protein binding of pravastatin].
    Ichimura Y; Takamatsu H; Ideuchi H; Oda M; Takeda K; Saitoh H
    Yakugaku Zasshi; 2015; 135(6):821-8. PubMed ID: 26028417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid.
    Tsutsumi Y; Maruyama T; Takadate A; Shimada H; Otagiri M
    Nephron; 2000 May; 85(1):60-4. PubMed ID: 10773757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A major inhibitor of phenytoin binding to serum protein in uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 48(4):310-4. PubMed ID: 3362278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Underestimation of serum albumin by the bromcresol purple method and a major endogenous ligand in uremia.
    Mabuchi H; Nakahashi H
    Clin Chim Acta; 1987 Jul; 167(1):89-96. PubMed ID: 3665090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between Plasma Levels of Anionic Uremic Toxins and Clinical Parameters in Hemodialysis Patients.
    Ichimura Y; Takamatsu H; Ideuchi H; Oda M; Takeda K; Saitoh H
    Yakugaku Zasshi; 2016; 136(8):1177-84. PubMed ID: 27477735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients?
    Eloot S; Van Biesen W; Glorieux G; Neirynck N; Dhondt A; Vanholder R
    PLoS One; 2013; 8(11):e76838. PubMed ID: 24236005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of renal transplantation on a major endogenous ligand retained in uremic serum.
    Mabuchi H; Nakahashi H; Hamajima T; Aikawa I; Oka T
    Am J Kidney Dis; 1989 Jan; 13(1):49-54. PubMed ID: 2643310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid assay for furancarboxylic acid accumulated in uremic serum using high-performance liquid chromatography and on-line mass spectrometry.
    Niwa T; Kawagishi I; Ohya N
    Clin Chim Acta; 1994 Apr; 226(1):89-94. PubMed ID: 8070137
    [No Abstract]   [Full Text] [Related]  

  • 17. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
    Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
    J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes.
    De Smet R; Dhondt A; Eloot S; Galli F; Waterloos MA; Vanholder R
    Nephrol Dial Transplant; 2007 Jul; 22(7):2006-12. PubMed ID: 17468506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography.
    Niwa T; Takeda N; Tatematsu A; Maeda K
    Clin Chem; 1988 Nov; 34(11):2264-7. PubMed ID: 3141084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a Clinically Relevant Uremic Toxin in Haemodialysis Patients?
    Luce M; Bouchara A; Pastural M; Granjon S; Szelag JC; Laville M; Arkouche W; Fouque D; Soulage CO; Koppe L
    Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29783628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.